AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms
The DOI matches its Crossref record; 4 of the 4 references it cites were found in a registry or an index.
Abstract
Myeloproliferative neoplasms (MPNs) are clonal hematopoietic stem cell disorders characterized by proliferation of one or more myeloid cell lineages. Some patients exhibit leukemic transformation (LT) by unknown mechanisms, and chemotherapy may increase the risk of LT. To clarify the molecular mechanisms of LT, gene alterations involved in LT from patients in the chronic phase (CP) of MPNs were identified. Among 18 patients who progressed to leukemia, AML1/RUNX1 mutations were detected in 5 patients at the LT but in none at the CP. To investigate the leukemogenic effect of AML1/RUNX1 mutants, the AML1D171N mutant was transduced into CD34+ cells from patients in the CP of MPNs. The D171N transduction resulted in proliferation of immature myeloid cells, enhanced self-renewal capacity, and proliferation of primitive progenitors. Taken together, these results indicate that AML1/RUNX1 point mutations may have a leukemogenic potential in MPN stem cells, and they may promote leukemic transformation in MPN.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Widespread occurrence of the JAK2 V617F mutation in chronic myeloproliferative disorders
Jones, A. V. (2005) · Blood · doi:10.1182/blood-2005-03-1320 · Cited by 843
Mesa, R. A., Li, C.-Y., Ketterling, R. P., Schroeder, G. S., Knudson, R. A., & Tefferi, A. (2005) · Blood · doi:10.1182/blood-2004-07-2864 · Cited by 389
Harada, H., Harada, Y., Niimi, H., Kyo, T., Kimura, A., & Inaba, T. (2004) · Blood · doi:10.1182/blood-2003-09-3074 · Cited by 281
Self-citationNiimi, H., Harada, H., Harada, Y., Ding, Y., Imagawa, J., Inaba, T., Kyo, T., & Kimura, A. (2006) · Leukemia · doi:10.1038/sj.leu.2404136 · Cited by 69
Self-citation
Cited by
New mutations and pathogenesis of myeloproliferative neoplasms
Vainchenker, W., Delhommeau, F., Constantinescu, S. N., & Bernard, O. A. (2011) · Blood · doi:10.1182/blood-2011-02-292102 · Cited by 395
Rocquain, J., Carbuccia, N., Trouplin, V., Raynaud, S., Murati, A., Nezri, M., Tadrist, Z., Olschwang, S., Vey, N., Birnbaum, D., et al. (2010) · BMC Cancer · doi:10.1186/1471-2407-10-401 · Cited by 171
“RUNX1 mutations are frequent in chronic myelomonocytic leukemia [19] but rare in myeloproliferative neoplasms except at the acute phase [35].”
BackgroundRUNX1 and RUNX1-ETO: roles in hematopoiesis and leukemogenesis
Lam, K. (2012) · Frontiers in Bioscience · doi:10.2741/3977 · Cited by 167
“Additional analyses of one of these mutated forms being transduced into human CD34 MPN cells demonstrated that it promoted proliferation, which as the authors suggested, may allow for leukemic transformation in patients with MPN (101).”
BackgroundFrequent deletions of JARID2 in leukemic transformation of chronic myeloid malignancies
Puda, A., Milosevic, J. D., Berg, T., Klampfl, T., Harutyunyan, A. S., Gisslinger, B., Rumi, E., Pietra, D., Malcovati, L., Elena, C., et al. (2012) · American Journal of Hematology · doi:10.1002/ajh.22257 · Cited by 105
Kubesova, B., Pavlova, S., Malcikova, J., Kabathova, J., Radova, L., Tom, N., Tichy, B., Plevova, K., Kantorova, B., Fiedorova, K., et al. (2018) · Leukemia · doi:10.1038/leu.2017.230 · Cited by 82
“Mol Cell Biol 2007 Aug; 27(15): 5336-5351.”
Metadata
- Authors
- Ding, Y., Harada, Y., Imagawa, J., Kimura, A., & Harada, H.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2009-12-10
- Volume
- 114
- Issue
- 25
- Pages
- 5201-5205
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W1981402051
- Cited by
- 71
- References
- 4
- FWCI
- 4.49
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. https://app.cochat.ai/papers/10.1182/blood-2009-06-223982
- The paper
- Ding, Y., Harada, Y., Imagawa, J., Kimura, A., & Harada, H. (2009). AML1/RUNX1 point mutation possibly promotes leukemic transformation in myeloproliferative neoplasms. Blood. https://doi.org/10.1182/blood-2009-06-223982
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.